Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

Danish investment firm Novo Holdings, which has invested in Manipal Hospitals and Qure.ai Technologies in India, has ...

These high-quality businesses have suffered recent share price setbacks. This writer thinks they're now worth considering for a Stocks and Shares ISA.

Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...

Eli Lilly is leading a push with other pharmaceutical companies to request a pause in the Biden administration's drug pricing negotiations, even as officials prepare to release a new list of ...